Breaking News, Collaborations & Alliances

Genisphere Expands LIMR Pact

To develop nanotherapeutics targeting cancers and eye diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genisphere and the Lankenau Institute for Medical Research (LIMR) have partnered to develop nanotherapeutics targeting cancers and eye diseases. This partnership expands an existing collaboration to identify inflammatory bowel disease biomarkers.   Genisphere will use its 3DNA dendrimer, which allows researchers to deliver a therapeutic agent to any target cell. It is manufactured from natural strands of DNA hybridized together to create high biocompatibility and low toxicity. With the dendrimer...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters